羧酸酯酶2对多发性骨髓瘤的临床意义探讨  

Clinical significance of carboxylesterase 2 in multiple myeloma

作　　者：李莺[1] 朱雯雯[1] 陈瑞妮 LI Ying;ZHU Wenwen;CHEN Ruini(Department of Blood Transfusion,First Affiliated Hospital of Nanjing Medical University,Nanjing,210029,China;School of Medicine and Holistic Integrative Medicine,Nanjing University of Chinese Medicine)

机构地区：[1]南京医科大学第一附属医院输血科,南京210029 [2]南京中医药大学医学院·整合医学学院

出　　处：《临床血液学杂志》2023年第6期406-408,共3页Journal of Clinical Hematology

基　　金：国家自然科学基金青年科学基金(No:81903657)。

摘　　要：目的:探讨羧酸酯酶2(carboxylesterase 2,CES2)在多发性骨髓瘤(multiple myeloma,MM)中的临床意义。方法:对2020至2021年确诊为MM患者69例,采用酶联免疫吸附试验测定检测治疗前及化疗后2周后血清CES2含量,与60例正常体检人群进行比较。同时比较不同分期、分型患者血清CES2差异。通过医院信息系统、实验室信息系统、输血信息管理系统收集患者基本资料、主要实验室检查结果及成分输血情况,分析CES2与MM疾病进程的相关性。结果:69例MM患者治疗前血清CES2平均含量为(24.35±5.98)ng/mL,明显高于正常对照的(5.69±1.62)ng/mL(P<0.05),治疗后为(15.68±3.83)ng/mL,较治疗前明显下降(P<0.05)。Ⅲ期患者CES2明显高于Ⅰ、Ⅱ期患者(P<0.05),不同分型间差异无统计学意义(P>0.05)。治疗前血清CES2含量与患者血清肌酐、β-2微球蛋白及乳酸脱氢酶呈正相关(P<0.05),治疗前血清CES2含量与患者血红蛋白、白蛋白呈负相关(P<0.05),病程中输注红细胞患者的治疗前血清CES2含量明显高于未输注红细胞患者(P<0.05)。结论:CES2对MM的疾病进程预测具有临床价值。Objective To investigate the clinical significance of carboxylesterase 2(CES2)in multiple myeloma(MM).Methods Enzyme-linked immunosorbent assay(ELISA)was used to measure serum CES2 content before treatment and 2 weeks after chemotherapy in 69 patients with MM diagnosed in our hospital from 2020 to 2021,and the difference was compared with the normal population.The difference of serum carboxylesterase 2 in patients with different stages and types was compared.Patients'basic information,major laboratory test results and component blood transfusion were collected through HIS,LIS and blood transfusion information management system to analyze the correlation between carboxylesterase 2 and the progression of multiple myeloma disease.Results The average content of serum CES2 in 69 MM patients before treatment was(24.35±5.98)ng/mL,which was higher than that in normal control(5.69±1.62)ng/mL(P<0.05),and after treatment was(15.68±3.83)ng/mL,which was significantly lower than that before treatment(P<0.05).The CES2 in stageⅢpatients was higher than those in stageⅠandⅡpatients(P<0.05),and no significant difference was found among different types(P>0.05).Serum CES2 content was positively correlated with serum creatinine andβ-2 microglobulin before treatment(P<0.05),and serum CES2 content was negatively correlated with hemoglobin and albumin of patients before treatment(P<0.05).Serum CES2 content in the patients receiving red blood cell infusion during the course of disease was higher than that in the patients without red blood cell infusion(P<0.05).Conclusion CES2 had clinical value in predicting the disease course of MM.

关 键 词：羧酸酯酶2 多发性骨髓瘤 输血 

分 类 号：R733.3[医药卫生—肿瘤] R457.1[医药卫生—临床医学]